The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     
6 pts

Opinion on  Protalix BioTherapeutics Inc (PLX)     Sector: Healthcare  >  Industry: Biotechnology & Drugs
rated strong buy

Sep 12, 2009 02:07 AM GMT
Return Risk
+2.71% LOW
Associate

Yesterday, Protalix BioTherapeutics, Inc. ( PLX - Snapshot Report ) announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to prGCD for the treatment of Gaucher disease, an enzyme disorder that can cause liver and neurological problems

PLX:  This call was made on 09/12/09 @ $7.36
Rating:   Positive   $7.36 (09/12/09)
Gain/Loss:   +8.29% in 84 days
Target:   $8.00 (+8.70%) in Three months


Add Comment

Be the first to comment on this story and earn 2 points.

Your Comment



ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 noshoes 21.10 +34.44% 381
2 Gerald Greene 18.14 +71.24% 211
3 stockmarketfunding.com 17.66 +25.60% 55
4 akiralegrand 13.47 +14.32% 62
5 anup2104 12.13 +74.22% 40


POPULAR STOCKS
Symbol Company Name Sentiment
RIMM Research in Motion Ltd
MCD McDonald's Corp.
C Citigroup Inc
WMT WalMart Stores Inc
SIRI Sirius Satellite Radio Inc
MA MasterCard Inc

TODAY'S HEADLINES

TODAY'S TOP PICKS

 
Protalix BioTherapeutics Inc (PLX)
   SocialPicks Sentiment:   

   This Quarter's Sentiment:
All:
100.0%
Top:
100.0%




Latest Picks by legan
Symbol SP Sentiment Rating Return Since
AOB Positive -0.73% 11/15/09
CHLN Positive +20.21% 11/11/09
FREE Positive -10.50% 10/22/09
MATK Positive -19.04% 10/11/09
ZIXI Positive -20.00% 10/11/09

View All >
   




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch